AR056890A1 - Quinolinas alquilsulfonamidas - Google Patents

Quinolinas alquilsulfonamidas

Info

Publication number
AR056890A1
AR056890A1 ARP060105444A ARP060105444A AR056890A1 AR 056890 A1 AR056890 A1 AR 056890A1 AR P060105444 A ARP060105444 A AR P060105444A AR P060105444 A ARP060105444 A AR P060105444A AR 056890 A1 AR056890 A1 AR 056890A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
halogen
cycloalkyl
independently selected
Prior art date
Application number
ARP060105444A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR056890A1 publication Critical patent/AR056890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de acuerdo con la formula (1), en la cual R1 se selecciona de H, alquilo C1-4, cicloalquilo C3-6 y alquilo C1-4OC(O)-; A es fenilo o cicloalquilo C3-7; R2 cada vez que aparece se selecciona en forma independiente de H, -OH, -NH2, -CN, halogeno, alquilo C1-6, cicloalquilo C3-7, alcoxi C1-8 y alcoxi C1-6 alquilo C1-6; n es 1, 2 o 3; R3 cada vez que aparece se selecciona en forma independiente de H, -OH, -NH2, -NO2, -CN, halogeno, alquilo C1-6, alcoxi C1-6 y alcoxi C1-6 alquilo C1-6; m es 1, 2 o 3; r es 1, 2 o 3, R4 se selecciona de alquilo C1-4, alcoxi C1-6 alquilo C1-6, cicloalquilo C3-7 y E-(CH2)p-, donde E se selecciona de -NR6R7, -SR6, -SO-alquilo C1-6, -SO2-alquilo C1-6, N+(O-)R6R7, -NR6SO2R7, arilo y un anillo heterocíclico aromático o no aromático de 5 o 6 miembros unido a N o C o un N-oxido del mismo, que tiene 1, 2, 3 o 4 átomos de nitrogeno o un N-oxido del mismo y p es 0, 1, 2, 3, 4 o 5; R5 cada vez que aparece se selecciona en forma independiente de H, -OH, -CN, halogeno, -R6, -OR6, -NR6R7, -SR6, -SOR6 y -SO2R6; q es 1; 2 o 3; R8 se selecciona de H, un grupo alquilo C1-5 recto o ramificado o un grupo cicloalquilo C3-5 en el cual dichos grupos no están sustituidos o están sustituidos con una o más porciones seleccionadas de -OH, =O, -NH2, -CN, halogeno, arilo y alcoxi C1-3; en la cual R6 y R7 cada vez que aparecen se seleccionan en forma independiente de H, un grupo alquilo C1-6 recto o ramificado, un grupo alquenilo o alquinilo C2-6 recto o ramificado y un grupo carbocíclico C3-7 que tiene cero, uno o dos enlaces dobles o triples, en los cuales dichos grupos no están sustituidos o están sustituidos con una o más porciones seleccionadas de -OH, =O, -NH2, -CN, halogeno, arilo y alcoxi C1-3; y, cuando R4 es E-(CH2)p- y dicho E del mismo, es un anillo heterocíclico aromático o no aromático de 5 o 6 miembros unido a N o C o un N-oxido del mismo, dicho E no está sustituido o tiene 1, 2 o 3 sustituyentes seleccionados en forma independiente de -OH, =O, -NH2, -CN, halogeno, alquilo C1-4, alcoxi C1-4, alquilo C1-4-CO-, -NR6R7, arilo y un anillo heterocíclico aromático o no aromático de 5 o 6 miembros que tiene 1, 2, 3 o 4 átomos de nitrogeno; y, cuando R1, R2, R3 o R4 es una porcion alquilo, cicloalquilo, alcoxi o alcoxialquilo, dichas porciones no están sustituidas o tienen 1, 2, 3, 4 o 5 sustituyentes seleccionados en forma independiente, cada vez que aparecen, de -OH, -NH2, -CN, fenilo y halogeno; estereoisomeros, enantiomeros, precursores hidrolizables in vivo y sus sales aceptables para uso farmacéutico.
ARP060105444A 2005-12-12 2006-12-11 Quinolinas alquilsulfonamidas AR056890A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74943105P 2005-12-12 2005-12-12
US82101606P 2006-08-01 2006-08-01

Publications (1)

Publication Number Publication Date
AR056890A1 true AR056890A1 (es) 2007-10-31

Family

ID=38163189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105444A AR056890A1 (es) 2005-12-12 2006-12-11 Quinolinas alquilsulfonamidas

Country Status (21)

Country Link
US (3) US20080293765A1 (es)
EP (1) EP1968944B1 (es)
JP (1) JP5165581B2 (es)
KR (1) KR20080075867A (es)
AR (1) AR056890A1 (es)
AU (1) AU2006325572B2 (es)
BR (1) BRPI0619746A2 (es)
CA (1) CA2633129A1 (es)
DK (1) DK1968944T3 (es)
EC (1) ECSP088546A (es)
ES (1) ES2571834T3 (es)
HK (1) HK1121759A1 (es)
HU (1) HUE029805T2 (es)
IL (1) IL191628A0 (es)
NO (1) NO20083029L (es)
PL (1) PL1968944T3 (es)
PT (1) PT1968944T (es)
RU (1) RU2421447C2 (es)
TW (2) TW201018662A (es)
UY (1) UY30001A1 (es)
WO (1) WO2007069977A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
AU2010209825A1 (en) * 2009-01-30 2011-08-11 F. Hoffmann-La Roche Ag Piperidine derivatives as NK3 receptor antagonists
CA2833232C (en) 2011-04-15 2018-05-22 University Of Massachusetts Surgical cavity drainage and closure system
JP6208148B2 (ja) 2012-01-24 2017-10-04 スミス アンド ネフュー インコーポレイテッド 多孔質構造の製作方法
AU2014255512A1 (en) 2013-04-19 2015-11-12 Astrazeneca Ab A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
GB201315846D0 (en) * 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
GB201503207D0 (en) 2015-02-26 2015-04-15 Univ Edinburgh Female health compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177096A (en) * 1989-10-25 1993-01-05 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof
US5248689A (en) * 1989-11-06 1993-09-28 Smithkline Beecham Corporation Substituted N-(imidazolyl)alkyl alanine derivatives
NZ238688A (en) * 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
FR2719311B1 (fr) 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
NZ287442A (en) 1994-05-27 1998-05-27 Smithkline Beecham Spa 4-substituted quinoline derivatives; medicaments; use as an nk3 receptor antagonist
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
TR199800767T2 (xx) * 1995-10-30 1998-07-21 Smithkline Beecham Corporation Proteaz engelleyicileri.
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
GB9524137D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
BR9611820A (pt) * 1995-11-24 1999-07-13 Smithkline Beecham Spa Derivados de quinolina
US6096739A (en) * 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
PE20000354A1 (es) 1998-04-03 2000-05-20 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
NZ511777A (en) 1998-11-20 2003-12-19 Smithkline Beecham S Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
KR20020012245A (ko) * 1999-05-27 2002-02-15 로렌스 티. 마이젠헬더 항균제로서의 비시클릭 옥사졸리디논
US6858630B2 (en) * 1999-12-06 2005-02-22 Smithkline Beecham Corporation Naphthimidazole derivatives and their use as thrombopoietin mimetics
US6248136B1 (en) * 2000-02-03 2001-06-19 Micell Technologies, Inc. Methods for carbon dioxide dry cleaning with integrated distribution
WO2002013825A1 (en) 2000-08-11 2002-02-21 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
NZ525324A (en) 2000-10-20 2005-03-24 Eisai Co Ltd Nitrogenous aromatic ring compounds
GB0027701D0 (en) * 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
US20040006135A1 (en) * 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
GB0228288D0 (en) 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228287D0 (en) 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7732442B2 (en) * 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
US20070244152A1 (en) 2004-03-25 2007-10-18 Lowy Martin T Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders
BRPI0510623A (pt) 2004-05-06 2007-10-30 Pfizer compostos de derivados de prolina e morfolina
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0509405D0 (en) 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
JP2008546767A (ja) * 2005-06-23 2008-12-25 アストラゼネカ・アクチエボラーグ Ｎｋ３受容体のモジュレーターとしてのキノリン３−スルホン酸エステル
WO2007018465A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Amide alkyl pyridiyl quinolines as nk3 receptor modulators
US20090215894A1 (en) 2005-08-12 2009-08-27 Regents Of The University Of California Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
JP2009524656A (ja) * 2006-01-27 2009-07-02 アストラゼネカ・アクチエボラーグ アミド置換キノリン
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina

Also Published As

Publication number Publication date
HUE029805T2 (en) 2017-03-28
IL191628A0 (en) 2008-12-29
ECSP088546A (es) 2008-07-30
TW201018662A (en) 2010-05-16
PL1968944T3 (pl) 2016-11-30
US20080021062A1 (en) 2008-01-24
JP2009519331A (ja) 2009-05-14
KR20080075867A (ko) 2008-08-19
EP1968944B1 (en) 2016-04-20
RU2421447C2 (ru) 2011-06-20
US20100029717A1 (en) 2010-02-04
UY30001A1 (es) 2007-07-31
US8071621B2 (en) 2011-12-06
CA2633129A1 (en) 2007-06-21
AU2006325572B2 (en) 2011-02-24
US20080293765A1 (en) 2008-11-27
BRPI0619746A2 (pt) 2011-10-11
DK1968944T3 (en) 2016-08-01
ES2571834T3 (es) 2016-05-27
RU2008121761A (ru) 2010-01-20
AU2006325572A1 (en) 2007-06-21
NO20083029L (no) 2008-07-09
PT1968944T (pt) 2016-07-29
WO2007069977A1 (en) 2007-06-21
US7608628B2 (en) 2009-10-27
EP1968944A1 (en) 2008-09-17
JP5165581B2 (ja) 2013-03-21
TW200804288A (en) 2008-01-16
EP1968944A4 (en) 2011-01-12
HK1121759A1 (zh) 2009-04-30

Similar Documents

Publication Publication Date Title
AR056890A1 (es) Quinolinas alquilsulfonamidas
AR068764A1 (es) N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah.
AR110051A2 (es) Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR064454A1 (es) Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR066421A1 (es) Compuestos derivados de piridona
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR057993A1 (es) Compuestos derivados de pirazol 1,2
AR056887A1 (es) Derivados de acido aril acetico y su uso como anti-inflamatorio
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
AR090868A1 (es) Composiciones plaguicidas y procesos relacionados con ellas
AR059329A1 (es) Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion
AR060807A1 (es) Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR080187A1 (es) Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen.
AR083578A1 (es) INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA
CO6341610A2 (es) Compuesto heterociclilo aromatico que contiene nitrogeno.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee